Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 655

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 2
Chunk 655
---
 remediation efforts will continue to take place. Management
is committed to maintaining a strong internal control environment. In response to the identified material weaknesses in the overall control
environment, management is currently implementing additional measures which include:

    ●
    Hired
    a new Chief Financial Officer during the second quarter of 2024 to bolster the Company’s internal technical accounting and
    financial reporting experience and provide bandwidth for the prior Chief Financial Officer to focus on the Company’s expanding
    clinical trial.
  
    ●
    Engaged
    a third-party consulting firm to assist with the preparation of SEC reporting and other technical accounting matters.

The
Company will continue to review and improve its internal controls over financial reporting to address the underlying causes of the material
weaknesses and control deficiencies. While the Company has added significant resources, particularly relevant to unusual and complex
accounting matters, and stock-based compensation accounting and reporting, its material weaknesses and control deficiencies will not
be fully remediated until the Company has concluded that its internal controls are operating effectively for a sufficient period of time.

Item
9B. Other Information

None.

Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not
applicable.

69

PART
III

Item
10. Directors, Executive Officers and Corporate Governance

MANAGEMENT

Our
directors and executive officers and their respective ages and titles are as follows:

    Name
     
    Age
     
    Position(s)
    and Office(s) Held

    Anatoly
    Dritschilo, M.D.
     
    80
     
    Chairman
    of the board of directors and Chief Executive Officer
  
    Timothy
    J. Lorber
     
    67
     
    Chief
    Financial Officer
  
    Michael
    Vander Hoek
     
    65
     
    VP
    for Operations and Regulatory, former Chief Financial Officer
  
    Peter
    Dritschilo
     
    55
     
    President
    and Chief Operating Officer
  
    Mira
    Jung, Ph.D.
     
    75
     
    Chief
    Scientific Officer
  
    Tyvin
    Rich, M.D.
     
    77
     
    Chief
    Clinical Officer
  
    Milton
    Brown, M.D., Ph.D.
     
    59
     
    Director
  
    Steven
    Richards
     
    56
     
    Independent